Rising Costs Hit Indian Drugmakers

Indian drugmakers are grappling with rising costs and falling exports. The strong US dollar makes imported materials like active pharmaceutical ingredients (APIs) and chemicals much more expensive. Expert Dinesh Dua explained that many essential items, from APIs to packaging, are priced in dollars, so a weaker rupee increases costs. Pharmexcil Chairman Namit Joshi added that this currency effect, combined with global disruptions, is driving up raw material and shipping expenses. The industry is especially vulnerable to issues from the West Asia conflict, which has hit supply chains and shipping costs. Although the government is offering customs duty relief on some petrochemicals until mid-2026, overall input costs remain high.

March Exports Plummet, Logistics Blamed

Indian pharmaceutical exports saw a sharp drop in March 2026, falling 23.17% year-on-year to $2.83 billion. This is the first monthly decrease in three years. While exports grew slightly overall for fiscal year 2025-26, the March slump highlights major challenges. Industry experts blame logistical issues from the West Asia conflict for the decline, not a lack of demand. Disrupted shipping routes, especially via Dubai, have caused longer delivery times, higher freight costs, and risk to sensitive medicines. Buyers in the US and Europe are also being cautious due to the global economic slowdown, leading to delayed orders and adjusted terms, alongside inventory adjustments at home.

Shift to High-Value Drugs: The New Strategy

To tackle these challenges, Indian drug companies are speeding up their move from selling many low-margin generic drugs to focusing on more complex, higher-value products. This includes complex generics, biologics, biosimilars, and specialty drugs, which command better prices and have longer patent protection. Companies are investing more in R&D and advanced manufacturing to compete in these areas. Government schemes like the Production-Linked Incentive (PLI) are helping boost local API production. The Nifty Pharma index, despite a recent dip, has held up well compared to the wider market. The sector's total market value is around ₹19.29 lakh crore, with a P/E ratio of 38.7, indicating investor belief in its future. Many companies also have strong finances, with low debt, supporting these R&D efforts.

Persistent Risks in the Pharma Shift

However, significant risks remain even with this shift. The industry's heavy reliance on imported APIs, especially from China, leaves it exposed to supply chain disruptions and currency swings. The West Asia conflict has underscored this vulnerability, raising the possibility of drug shortages and higher costs if problems continue. While the Indian government has taken steps like duty exemptions on some chemicals, ongoing global instability could weaken these measures. Moving into complex generics and biologics also demands major R&D spending and meeting strict global rules from bodies like the US FDA and EMA. Compliance costs are rising fast, requiring big investments in digital quality systems. Analysts warn that while generics are still important, their profit margins are shrinking. Relying too much on them without a successful shift to higher-value drugs could hurt profits. Potential US tariffs, while mostly affecting branded drugs now, could also impact market confidence.

Outlook: Value Over Volume for Long-Term Growth

Analysts expect moderate growth for the industry, with revenues predicted at 7-9% for FY2026, driven by domestic sales and European markets, though US growth may slow. Profit margins are likely to stay strong, helped by more specialty products. Long-term, the Indian pharma sector could reach $120 billion-$130 billion by 2030. This growth depends on managing regulatory hurdles, innovating in complex drugs and biologics, and reducing supply chain risks. The industry is moving from a model focused on selling large volumes to one focused on higher value, aiming for global recognition for quality and reliability over just low costs. However, ongoing geopolitical risks and the global economic slowdown will test these plans.